IP Library Granted Patent US 8,133,497
Granted Patent B2
US 8,133,497 · App. 12/559,278 · Granted Mar 13, 2012

Systems and methods for delivery of a therapeutic agent

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,133,497
App. No.
12/559,278
Granted
Mar 13, 2012
Kind
B2
Abstract

Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

Claims (44)

1. A system for delivering toxins to target cells in a mammalian target, said system comprising:

a toxin consisting of a light chain of a neurotoxin fragment;

a catheter or other structure adapted to introduce the toxin to a region adjacent the target cells; and

an energy applicator configured to apply energy to the target cells at a level sufficient to cause pores to form in the cell membranes of the target cells to allow the toxin to pass through said pores into the target cells.

2. A system as in claim 1 , wherein the energy applicator is adapted to selectively apply energy to target cells within the region where toxin has been introduced.

3. A system as in claim 1 , wherein the energy applicator is adapted to apply energy non-selectively within the region where toxin has been introduced.

4. A system as in claim 1 , wherein the toxin is an active toxin fragment.

5. A system as in claim 4 , wherein the active fragment is selected from the group consisting of botulinum toxin fragments, ricin fragments, exotoxin A fragments, diphtheria toxin fragments, cholera toxin fragments, and tetanus toxin fragments.

6. A system as in claim 5 , wherein the active fragment consists of the botulinum light chain (BoNT-LC).

7. A system as in claim 6 , wherein the light chain fragment is derived from at least one of botulinum toxins A, B, C, D, E, F, and G.

8. A system as in claim 1 , wherein the energy applicator is adapted to apply an electric pulse of between 1V and 500V to the target region.

9. A system as in claim 8 , wherein the electric pulse is radio frequency (RF) energy.

10. A system as in claim 9 , wherein the RF energy is pulsed for durations between 5 microseconds to 100 milliseconds.

11. A system as in claim 8 , wherein the electric pulse is produced by a DC power source.

12. A system as in claim 8 , wherein the electric pulse is produced by an AC power source.

13. A system as in claim 1 , wherein the energy applicator is adapted to apply ultrasonic energy to the targeted region.

14. A system as in claim 13 , wherein the energy applicator is adapted to apply focused ultrasound to the targeted region.

15. A system as in claim 1 , wherein the energy applicator is adapted to apply an x-ray beam to the targeted region.

16. A system as in claim 1 , wherein the energy applicator is adapted to apply microwaves to the targeted region.

17. A system as in claim 1 , wherein the catheter comprises a needle for delivering the toxin.

18. A system as in claim 1 , wherein the catheter comprises a port for aerosolizing the toxin.

19. A system as in claim 1 , wherein the catheter comprises a balloon for deflecting one or more ports against target tissue.

20. A system as in claim 19 , wherein the balloon comprises the one or more ports.

21. A system as in claim 1 , wherein the energy applicator is on the catheter.

22. A system as in claim 21 , wherein the energy applicator applies acoustic energy from a transducer on the catheter.

23. A system as in claim 21 , wherein the energy applicator applies electrical energy from an electrode on the catheter.

24. A system as in claim 1 , wherein the applicator applies energy from a source external to the patient.

25. A system as in claim 24 , wherein the source is an acoustic energy transducer.

26. A system as in claim 25 , wherein the acoustic energy transducer is focused ultrasound transducer.

27. A system for delivering toxins to target cells in a mammalian target, said system comprising:

a toxin delivery structure adapted to introduce a toxin to a region adjacent the target cells;

an acoustic energy delivery element configured for applying acoustic energy to the target cells under conditions which causes poration of the cell membranes to enhance delivery of the toxin; and

a toxin delivered by the catheter, the toxin consisting of a light chain of a neurotoxin fragment, wherein the delivery element is configured to deliver acoustic energy at a level sufficient to result in poration of the cell membranes to allow the toxin to pass into the target cells.

28. A system as in claim 27 , wherein the acoustic energy delivery element comprises an ultrasound transducer.

29. A system as in claim 27 , wherein the acoustic energy delivery element is adapted to selectively apply the acoustic energy to the target cells within the region where toxin has been introduced.

30. A system as in claim 27 , wherein the toxin is an active toxin fragment.

31. A system as in claim 30 , wherein the active fragment is selected from the group consisting of botulinum toxin fragments, ricin fragments, exotoxin A fragments, diphtheria toxin fragments, cholera toxin fragments, and tetanus toxin fragments.

32. A system as in claim 30 , wherein the active fragment consists of the botulinum light chain (BoNT-LC).

33. A system as in claim 32 , wherein the light chain fragment is derived from at least one of botulinum toxins A, B, C, D, E, F, and G.

34. A system as in claim 27 , wherein the acoustic energy delivery element is adapted to apply focused ultrasound to the targeted region.

35. A system as in claim 27 , wherein the toxin delivery structure comprises a needle for delivering the toxin.

36. A system as in claim 27 , wherein the toxin delivery structure comprises a port for aerosolizing the toxin.

37. A system as in claim 27 , wherein the toxin delivery structure comprises a balloon for deflecting one or more ports against target tissue.

38. A system as in claim 37 , wherein the balloon comprises the one or more ports.

Assignments (5)
SECURITY INTEREST Recorded Oct 16, 2024
From: NUVAIRA, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND 1, LP
Reel/Frame 069175/0918 →
RELEASE OF SECURITY INTEREST Recorded Jun 21, 2023
From: INNOVATUS LIFE SCIENCES LENDING FUND I, LP
To: NUVAIRA, INC.
Reel/Frame 064017/0683 →
SECURITY INTEREST Recorded Dec 21, 2021
From: NUVAIRA, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND 1, LP
Reel/Frame 058561/0979 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2011
From: DEEM, MARK E.; GIFFORD, HANSON
To: THE FOUNDRY INC.
Reel/Frame 027215/0590 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2011
From: THE FOUNDRY, INC.
To: THE FOUNDRY, LLC
Reel/Frame 027215/0619 →